Apollo: Olaparib In Pancreatic Cancer With A Brca1/2 Or Palb2 Mutation

APOLLO: olaparib in pancreatic cancer with a BRCA1/2 or PALB2 mutation

POLO: maintenance olaparib in BRCA1/2 metastatic pancreatic cancer

EA2192/APOLLO Research Study for BRCA- or PALB2-Related Pancreatic Cancer

ECOG-ACRIN Cancer Research Group

PARP Inhibitor Olaparib Exceeds Expectations in BRCA+ Pancreatic Cancer Management

Targeted Oncology

PARP Inhibitors gBRCA1/2-Mutated Pancreatic Cancer

[pancreas] Role of olaparib in stage 4 pancreatic cancer patients with BRCA mutations

David Lauren Research | Oncology in 3 minutes.

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them t...

Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic Cancer

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients wi...

POLO: Olaparib as maintenance treatment for metastatic pancreatic cancer

Olaparib in metastatic pancreatic cancer, the POLO trial

PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations

Treatment Options for Patients with BRCA1/2

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Clinical Trial Available for Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

UT Health San Antonio MD Anderson Cancer Center

Olaparib for BRCA Positive Pancreatic Cancer Patients

Expert Discusses Olaparib for BRCA+ Pancreatic Cancer

OlympiA: Adjuvant olaparib delays recurrence of BRCA-mutant breast cancer | Judy Garber

Medicine Matters oncology

BRCA Mutations and Pancreatic Cancer: What You Need to Know

Basser Center for BRCA